Flagstar Bank NA vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.69B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 5.4× Flagstar Bank NA's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| FLG | RPRX | |
|---|---|---|
Market Cap | $4.69B | $25.27B |
Volume | 6,174,553 | 3,671,183 |
Sector | Financials | Health |
52-Week High | $15.36 | $63.96 |
52-Week Low | $10.72 | $35.44 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $15.23B | $32.50B |
Dividend Yield | 0.35% | 1.66% |
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.30, down 2.25% today, with a bearish technical signal despite bullish oscillators. The stock shows mixed fundamentals with a high P/E of 376.67 but trades below book value (P/B 0.61). Recent Q2 2026 earnings missed expectations, though the company reported its third consecutive profitable quarter. Analyst consensus remains strongly bullish with a $17.07 price target and no sell ratings.
The outlook suggests potential upside from current depressed levels, supported by analyst optimism and strategic initiatives like the $250M share repurchase program. Key risks include earnings volatility, competitive pressures in regional banking, and sensitivity to interest rate changes. The stock presents a value opportunity but requires careful monitoring of execution on profitability targets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →